RecruitingPhase 3NCT06528444

Clinical Trial Evaluating the Efficacy and Safety of Dexamethasone Compared to Placebo in Patients With Severe Influenza

Randomized, Double-blind, Multicenter, Phase III Clinical Trial Evaluating the Efficacy and Safety of Dexamethasone Compared to Placebo in Patients With Severe Influenza


Sponsor

Instituto de Investigación Sanitaria y Biomédica de Alicante

Enrollment

42 participants

Start Date

Oct 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Clinical trial with an active ingredient of a pharmaceutical specialty marketed in Spain vs. placebo. Randomized, double-blind, multicenter phase III clinical trial that evaluates the efficacy and safety of dexamethasone compared to placebo in patients with severe influenza.


Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Grup 1 placebo and a drug called Grup 2 dexametasona for people with influenza. The study is currently recruiting participants at 2 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGrup 1 placebo

placebo 1 capsule (6 mg) /day for 7 days.

DRUGGrup 2 dexametasona

dexamethasone 1 capsule (6 mg)/day for 7 days


Locations(2)

Hospital General Universitario Dr. Balmis de Alicante (centro coordinador)

Alicante, Spain

Hospital General Universitario de Elche

Elche, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06528444


Related Trials